论文部分内容阅读
目的探讨重组干扰素联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法将2011年12月—2012年12月72例慢性乙肝患者随机分成二组:对照组36例单纯采用重组人干扰素α-2b治疗;治疗组36例采用重组人干扰素α-2b+阿德福韦酯治疗;比较二组临床疗效、乙肝病毒脱氧核糖核酸(HBV DNA)转阴率、乙肝病毒e抗原(HBeAg)转阴率、HBeAg血清转换率和患者肝功能指标水平的变化情况。结果治疗组的总有效率明显高于对照组(P<0.05);治疗组治疗后的HBV DNA转阴率、HBeAg转阴率、HBeAg血清转换率均显著高于对照组(P<0.05);治疗组患者治疗后的丙氨酸转氨酶(ALT)、冬氨酸转氨酶(AST),与对照组差异无统计学意义。结论重组人干扰素联合阿德福韦酯治疗慢性乙型肝炎,提高乙肝病毒标志物转阴率,改善肝功能水平。
Objective To investigate the clinical efficacy of recombinant interferon combined with adefovir dipivoxil in the treatment of chronic hepatitis B patients. Methods Seventy-two chronic hepatitis B patients from December 2011 to December 2012 were randomly divided into two groups: control group, 36 cases were treated with recombinant human interferon α-2b alone; 36 cases treated with recombinant human interferon α-2b + Fu Wei ester; The clinical efficacy, HBV DNA negative rate, HBeAg negative rate, HBeAg seroconversion rate and liver function index of the two groups were compared. Results The total effective rate of the treatment group was significantly higher than that of the control group (P <0.05). After treatment, the HBV DNA negative rate, HBeAg negative rate and HBeAg seroconversion rate in the treatment group were significantly higher than those in the control group (P <0.05). The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the treatment group were not significantly different from the control group. Conclusion Recombinant human interferon combined with adefovir dipivoxil treatment of chronic hepatitis B, improve the negative rate of hepatitis B virus markers, improve liver function.